Nilkamal Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "The Press Release on results for the quarter and year ended March 31, 2025 ".
NILKAMAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nilkamal's board approved audited standalone and consolidated results for Q4 and FY ended March 31, 2025, with the statutory auditor (S R B C & Co LLP) issuing an unmodified opinion. Standalone FY25 revenue from operations rose modestly to Rs. 3,23,931.79 lakhs (vs Rs. 3,13,410.96 lakhs in FY24), but net profit after tax fell to Rs. 10,680.53 lakhs (vs Rs. 12,243.19 lakhs). Consolidated FY25 revenue grew to Rs. 3,31,274.06 lakhs with PAT of Rs. 9,127.08 lakhs (vs Rs. 10,731.22 lakhs). Operating margin slipped to 8.22% on standalone basis (from 8.89%) and net margin compressed to 2.82% (from 3.42%). The board recommended a final dividend of Rs. 20 per share (200%) subject to shareholder approval. The company also announced acquisition of Imedfurns' healthcare business for Rs. 4 crore (payable over 4 years), continuation of Mr. Sharad V. Parekh as Chairman for 4 years, and appointment of new secretarial auditor. AGM is scheduled for July 18, 2025.
Mixed bag for shareholders: decent top-line growth and a healthy 200% dividend reward shareholders, but declining profits and margin compression may weigh on sentiment. The small Rs. 4 crore healthcare acquisition is a minor diversification move and not material to overall business.